Lipid-lowering, antioxidant, and anti-inflammatory effects of Erythrina speciosa and its triterpenoids in acute dyslipidemia.
Elsayed Rasha H RH, El-Toumy Sayed A SA, Kamel Emadeldin M EM, Ahmed Sayed A SA et al.
Dyslipidemia is a health concern that contributes to metabolic and cardiovascular complications. The present study evaluated the anti-dyslipidemic potential of the chloroform fraction of Erythrina speciosa leaves and its isolated constituents, with particular emphasis on lipid regulation, redox balance, and inflammatory mediators. Chromatographic separation of the chloroform fraction led to the isolation of five triterpenoids, reported here for the first time from E. speciosa. The biological activity was assessed in a poloxamer-407-induced acute hyperlipidemia model in rats. Treatment with the chloroform fraction, isolated compounds, or atorvastatin significantly attenuated elevations in serum total cholesterol and triglycerides and improved low-density lipoprotein-cholesterol (LDL-C). These effects were accompanied by restoration of lipoprotein lipase (LPL) activity, upregulation of hepatic LDL receptor (LDL-R), downregulation of fatty acid synthase (FAS), and suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA) reductase. Moreover, E. speciosa and its triterpenoids markedly alleviated oxidative stress and inflammation, as evidenced by reduced malondialdehyde (MDA), nitric oxide (NO), nuclear factor-kappaB (NF-κB) p65, tumor necrosis factor (TNF)-α, and interleukin (IL)- 1β and enhanced antioxidants. Molecular docking provided supportive computational evidence by predicting favorable binding interactions of the isolated compounds with NF-κB p65, LDL-R PCSK9 binding domain, and FAS. In conclusion, E. speciosa and its triterpenoids are promising candidates for the management of dyslipidemia and related inflammatory and oxidative disturbances.